依洛尤单抗对无心肌梗死或卒中史患者死亡率的影响:VESALIUS-CV 预设分析
中位随访 4.6 年显示,依洛尤单抗组全因死亡 5 年 Kaplan-Meier 率为 7.9%,低于安慰剂组 9.7%(HR 0.80,95%CI 0.70-0.91,P=0.0005)。结果支持在该高危人群中用依洛尤单抗改善生存。
要点
- 无既往心梗或卒中的高危患者中,依洛尤单抗较安慰剂降低全因死亡风险 20%。
- 心血管死亡、非心血管死亡和原因不明死亡方向一致,均支持依洛尤单抗获益。
- 对非心血管死亡的影响可能主要通过预防非致死性心血管事件介导。
核心结论
- 结果支持在无既往心肌梗死或卒中的高危患者中使用依洛尤单抗改善生存,包括无动脉粥样硬化但 LDL-C≥90 mg/dL 的高危糖尿病患者。
研究设计与样本
- 入组标准为既往无心肌梗死或卒中,合并动脉粥样硬化或高危糖尿病,且 LDL-C≥90 mg/dL,或非 HDL-C≥120 mg/dL,或载脂蛋白 B≥80 mg/dL。
- 患者随机接受依洛尤单抗或安慰剂,中位随访 4.6 年(四分位距 4.0-5.2)。
主要发现
- 共 973 例(7.9%)患者死亡,其中心血管原因 351 例(36%),非心血管原因 497 例(51%),原因不明 125 例(13%)。
- 依洛尤单抗组全因死亡 434 例,5 年 Kaplan-Meier 率为 7.9%;安慰剂组 539 例,5 年 Kaplan-Meier 率为 9.7%。
- 全因死亡风险比为 0.80(95%CI 0.70-0.91,P=0.0005),心血管死亡 HR 0.79(95%CI 0.64-0.98)。
- 非心血管死亡 HR 0.85(95%CI 0.71-1.01),原因不明死亡 HR 0.64(95%CI 0.45-0.92)。
- 多状态模型提示,依洛尤单抗对非心血管死亡的影响 78%(自举法四分位距 71%-92%)由预防先前非致死性心血管事件驱动。
关键数值与推荐
- 入组血脂标准为 LDL-C≥90 mg/dL,或非 HDL-C≥120 mg/dL,或载脂蛋白 B≥80 mg/dL。
- 依洛尤单抗组全因死亡数 434 例(5 年 Kaplan-Meier 率 7.9%),安慰剂组 539 例(9.7%)。
- 心血管死亡:依洛尤单抗组 156 例(2.8%),安慰剂组 195 例(3.6%)。
- 非心血管死亡:依洛尤单抗组 229 例(4.2%),安慰剂组 268 例(5.0%)。
- 原因不明死亡:依洛尤单抗组 49 例(1.1%),安慰剂组 76 例(1.4%)。
临床怎么用
- 对既往无心肌梗死或卒中的高危动脉粥样硬化或高危糖尿病患者,可考虑用依洛尤单抗降低死亡风险。
- 随机化后发生非致死性心梗、缺血性卒中或缺血驱动的动脉血运重建,会增加随后 4 年内非心血管死亡风险。
- 全因死亡获益在不同年龄、性别、地区、种族、基线 LDL-C 和背景降脂治疗下保持一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evolocumab, a PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor, significantly reduced the risk of cardiovascular events in patients without previous myocardial infarction or stroke in the VESALIUS-CV trial (Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke). However, mortality results have yet to be fully characterized. METHODS: VESALIUS-CV was a double-blind study of 12 257 patients (median age, 66 years [interquartile range, 60-71]; 43% women) with qualifying atherosclerosis or high-risk diabetes without previous myocardial infarction or stroke, and low-density lipoprotein-cholesterol ≥90 mg/dL (or non-high-density lipoprotein-C ≥120 mg/dL or apolipoprotein B ≥80 mg/dL) who were randomized to evolocumab or placebo. Prespecified mortality outcomes of interest included all-cause mortality, subtypes of death (including cardiovascular [CV] and non-CV), and timing of events. Non-CV mortality was further investigated using multistate modeling to assess the contribution of prevention of nonfatal CV events (myocardial infarction, ischemic stroke, and ischemia-driven arterial revascularization) to non-CV mortality. RESULTS: Over a median of 4.6 years (interquartile range, 4.0-5.2), 973 (7.9%) patients died: 351 (36%) of CV causes, 497 (51%) of non-CV causes, and 125 (13%) of undetermined cause. All-cause mortality rates were 20% lower with evolocumab compared with placebo: 434 deaths (5-year Kaplan-Meier rate of 7.9%) with evolocumab versus 539 deaths (9.7%) with placebo (hazard ratio, 0.80, 95% CI, 0.70-0.91; P=0.0005). There was consistency of benefit for CV death (156 deaths [2.8%] versus 195 [3.6%]; hazard ratio, 0.79; 95% CI, 0.64-0.98), non-CV death (229 [4.2%] versus 268 [5.0%]; hazard ratio, 0.85; 95% CI, 0.71-1.01), and deaths of undetermined cause (49 [1.1%] versus 76 [1.4%]; hazard ratio, 0.64; 95% CI, 0.45-0.92). Results were consistent regardless of age, sex, region, race, qualifying atherosclerosis or high-risk diabetes, baseline low-density lipoprotein-cholesterol, or background lipid therapy. Postrandomization nonfatal myocardial infarction, ischemic stroke, and ischemia-driven arterial revascularization were associated with increased risk of subsequent non-CV death within the next 4 years, with the majority occurring during the first year after the event. Multistate modeling suggested the observations regarding non-CV death with evolocumab was largely (78%; bootstrap interquartile range, 71-92%) driven by the prevention of antecedent nonfatal CV events. CONCLUSIONS: These results support using evolocumab to improve survival in high-risk patients who have not experienced a previous myocardial infarction or stroke, including those with high-risk diabetes without qualifying atherosclerosis with low-density lipoprotein-cholesterol ≥ 90 mg/dl (or non-high-density lipoprotein-cholesterol ≥ 120 mg/dl or apolipoprotein B ≥ 80 mg/dl). REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03872401.
引用
- Giugliano, Bohula, Bellavia, et al. Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial. Circulation. 2026. PMID: 42670293. doi:10.1161/CIRCULATIONAHA.126.082436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。